HK1049184A1 - 具有增强抗凝血效能的抗组织因子抗体 - Google Patents

具有增强抗凝血效能的抗组织因子抗体 Download PDF

Info

Publication number
HK1049184A1
HK1049184A1 HK03101227.0A HK03101227A HK1049184A1 HK 1049184 A1 HK1049184 A1 HK 1049184A1 HK 03101227 A HK03101227 A HK 03101227A HK 1049184 A1 HK1049184 A1 HK 1049184A1
Authority
HK
Hong Kong
Prior art keywords
tissue factor
antibodies
factor antibodies
enhanced anticoagulant
anticoagulant potency
Prior art date
Application number
HK03101227.0A
Other languages
English (en)
Chinese (zh)
Inventor
K. Kirchhofer Daniel
G. Lowe David
G. Presta Leonard
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HK1049184A1 publication Critical patent/HK1049184A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK03101227.0A 2000-03-16 2001-03-08 具有增强抗凝血效能的抗组织因子抗体 HK1049184A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18977500P 2000-03-16 2000-03-16
US189775P 2000-03-16
PCT/US2001/007501 WO2001070984A2 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency

Publications (1)

Publication Number Publication Date
HK1049184A1 true HK1049184A1 (zh) 2003-05-02

Family

ID=22698717

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101227.0A HK1049184A1 (zh) 2000-03-16 2001-03-08 具有增强抗凝血效能的抗组织因子抗体

Country Status (6)

Country Link
EP (1) EP1263960A2 (enrdf_load_stackoverflow)
JP (1) JP2003527861A (enrdf_load_stackoverflow)
AU (2) AU5081401A (enrdf_load_stackoverflow)
CA (1) CA2402596A1 (enrdf_load_stackoverflow)
HK (1) HK1049184A1 (enrdf_load_stackoverflow)
WO (1) WO2001070984A2 (enrdf_load_stackoverflow)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223491C (en) 1995-06-07 2010-08-10 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
GB0027750D0 (en) 2000-11-14 2000-12-27 Trisport Ltd Studded footwear
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
IL160998A0 (en) * 2001-10-02 2004-08-31 Novo Nordisk As Human tissue factor antibodies
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
EP1476186A1 (en) * 2002-02-22 2004-11-17 Prophy Med AB Use of an inhibitor or antagonist against tissue factor
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004041302A1 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004068931A2 (en) * 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
CN100353997C (zh) 2003-02-28 2007-12-12 中外制药株式会社 稳定的含蛋白质的制剂
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CN100528229C (zh) * 2003-05-30 2009-08-19 森托科尔公司 用抗组织因子抗体抑制肿瘤生长的方法
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CA2526080A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US6904707B2 (en) 2003-07-01 2005-06-14 Softspikes, Llc Indexable shoe cleat with improved traction
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CN101970493A (zh) * 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA2802782C (en) 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
CA2906037C (en) 2013-03-15 2021-08-03 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
HK1225298A1 (zh) 2013-07-23 2017-09-08 Biocon Limited Cd6结合配对体的使用和以其为基础的方法
WO2015115656A1 (ja) * 2014-02-03 2015-08-06 独立行政法人国立がん研究センター 抗Ｔｉｓｓｕｅ Ｆａｃｔｏｒモノクローナル抗体
WO2018073734A1 (en) 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
BR112023000455A2 (pt) * 2020-07-10 2023-03-28 Iconic Therapeutics Inc Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
WO2024102818A1 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Combination tumor therapy with thrombosis initiation and platelet recruitment
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596065A (en) * 1897-12-28 Ejector for ashes
DE3237880A1 (de) * 1982-10-13 1984-04-19 Robert Bosch Gmbh, 7000 Stuttgart Kodierspeicher, insbesondere fuer werkstuecktraeger in der fliessfertigung
JPS60188045A (ja) * 1984-03-08 1985-09-25 リサーチ・コーポレイシヨン 保存安定性魚肉ベース製品
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
CA2325346A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Also Published As

Publication number Publication date
AU2001250814B2 (en) 2007-02-15
JP2003527861A (ja) 2003-09-24
CA2402596A1 (en) 2001-09-27
WO2001070984A2 (en) 2001-09-27
EP1263960A2 (en) 2002-12-11
AU5081401A (en) 2001-10-03
WO2001070984A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
HK1049184A1 (zh) 具有增强抗凝血效能的抗组织因子抗体
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002024149A3 (en) Immunogen comprising ligand bound hiv envelpe protein
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
WO2005007809A3 (en) Antibodies and fusion proteins that include engineered constant regions
WO2002081646A3 (en) Epitope sequences
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2002002636A3 (en) Membrane associated protein zupari
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
IL166632A (en) Antibody that binds an alpha-fetoprotein antigen and fusion protein comprising such
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
MXPA03007319A (es) Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
WO2003029458A3 (de) Verfahren zur herstellung von protein-bibliotheken und zur selektion von proteinen daraus
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
EP1308507A3 (en) HCV anti-core monoclonal antibodies
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
WO2004009785A3 (en) IgG Fc/HIV-gp120/C3d FUSION PROTEIN
WO1997011968A3 (en) A gene associated with liver neoplastic disease
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AUPR546801A0 (en) Recombinant antibodies